36 results on '"Dahlof, Bjorn"'
Search Results
2. Abstract 122: The Eicosanoid Analogue Cs585 Represents A First-in-class In Prevention Of Platelet Activation And Thrombosis Through Direct Activation Of The Prostacyclin Receptor
3. CS585 IS A NOVEL ORALLY AVAILABLE PROSTACYCLIN RECEPTOR AGONIST WITH LONG-TERM IN VIVO INHIBITION OF PLATELETS AND THROMBOSIS FORMATION IN MOUSE WITHOUT INCREASED RISK OF BLEEDING
4. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase
5. LBOS 01-04 THE TRUE INCIDENCE OF STATIN -RELATED ADVERSE EVENTS IN HYPERTENSIVE PATIENTS REVEALED BY COMPARISON OF BLINDED AND UN-BLINDED USE OF STATIN IN THE ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL (ASCOT)
6. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy
7. Transcranial Laser Therapy in Acute Stroke Treatment
8. Blood pressure measurement reliability among different racial-ethnic groups in a stroke prevention study
9. RELATIONSHIP OF INCIDENT ATRIAL FIBRILLATION TO RENAL FUNCTION IN HYPERTENSIVE PATIENTS WITH ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY: THE LIFE STUDY
10. LOWER ACHIEVED SYSTOLIC PRESSURE (≤130 MM HG) IS ASSOCIATED WITH WORSE RENAL FUNCTION BUT A SLOWER DECLINE IN GFR IN HYPERTENSIVE PATIENTS WITH ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY: THE LIFE STUDY
11. DOES NEW-ONSET AF LEAD TO CONGESTIVE HEART FAILURE AND VICE VERSA IN HYPERTENSIVE PATIENTS?
12. Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk Patients With Hypertension and Coronary Artery Disease
13. Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension
14. STATIN USE AND RISK OF NEW DIABETES MELLITUS IN HYPERTENSivE PATIENTS: THE LIFE STUDY
15. RELATIONSHIPS BETWEEN SYSTOLIC BLOOD PRESSURE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HIGH RISK HYPERTENSION: AN ANALYSIS OF THE ACCOMPLISH TRIAL
16. LOW IN-TREATMENT HDL CHOLESTEROL LEVELS STRONGLY PREDICT THE DEVELOPMENT OF NEW STROKE: THE LIFE STUDY
17. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
18. LOW IN-TREATMENT HDL CHOLESTEROL LEVELS STRONGLY PREDICT SUDDEN CARDIAC DEATH IN HYPERTENSIVE PATIENTS: THE LIFE STUDY
19. Renal outcomes in hypertensive Black patients at high cardiovascular risk
20. ASSOCIATION OF HIGH SERUM GLUCOSE LEVELS WITH LOW HDL CHOLESTEROL LEVELS IN NON-DIABETIC HYPERTENSIVE PATIENTS: IMPLICATIONS FOR THE DEVELOPMENT OF NEW DIABETES
21. INFLUENCE OF DIABETES ON LEFT VENTRICULAR MASS REGRESSION WITH ALISKIREN, LOSARTAN OR BOTH
22. Coronary heart disease benefits from blood pressure and lipid-lowering
23. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension
24. Effectiveness and Safety of Transcranial Laser Therapy for Acute Ischemic Stroke
25. Abstract 2281: Mitral E Wave Deceleration Time to Peak E Velocity Ratio And Cardiovascular Outcome in Hypertensive Patients During Anti-Hypertensive Treatment: the LIFE Echo-Substudy.
26. Infrared Laser Therapy for Ischemic Stroke: A New Treatment Strategy
27. The Effects of Losartan Compared to Atenolol on Stroke in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy. The LIFE Study
28. Losartan reduces hospitalization for heart failure in patients with diabetes and no prior history of heart failure
29. Association of left ventricular hypertrophy regression and heart rate reduction with determinants of myocardial oxygen consumption and cardiovascular events: The LIFE study
30. Hypertensive patients with diabetes have less regression of electrocardiographic left ventricular hypertrophy in response to antihypertensive therapy: The LIFE study
31. Prognostic significance of left ventricular hypertrophy during treatment of hypertension: The LIFE study
32. Gender differences in regression of electrocardiographic left ventricular hypertrophy in response to antihypertensive therapy: The LIFE study
33. Regression of echocardiographic left ventricular hypertrophy in relation to resolution versus persistence of electrocardiographic strain after one year of antihypertensive therapy: the LIFE study
34. Relations of diastolic left ventricular filling to systolic chamber and myocardial contractility in hypertensive patients with left ventricular hypertrophy (the PRESERVE study)
35. Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reactions
36. Antihypertensive effect of a new dihydropyridine calcium antagonist, PN 200-110 (isradipine), combined with pindolol
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.